Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202303710 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Lei Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu,…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Hepatic Stellate Cells, Micelles, Nanomedicine. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Diagnosing and treating liver fibrosis is a challenging yet crucial endeavor due to its complex pathogenesis and risk of deteriorating into cirrhosis, liver failure, and even hepatic cancer. Herein, a silica cross‐linked micelles (SCLMs) based nano‐system is developed for both diagnosing and treating liver fibrosis. The SCLMs are first modified with peptide CTCE9908 (CT‐SCLMs) and can actively target CXCR4, which is overexpressed in activated hepatic stellate cells (HSCs). To enable diagnosis, an ONOO − ‐responded near‐infrared fluorescent probe NOF2 is loaded into the CT‐SCLMs. This nano‐system can target the aHSCs and diagnose the liver fibrosis particularly in CCl 4 ‐induced liver damage, by monitoring the reactive nitrogen species. Furthermore, a step is taken toward treatment by co‐encapsulating two anti‐fibrosis drugs, silibinin and sorafenib, within the CT‐SCLMs. This combined approach results in a significant alleviation of liver injury. Symptoms associated with liver fibrosis, such as deposition of collagen, expression of hydroxyproline, and raised serological indicators show notable improvement. In summary, the CXCR4‐targeted nano‐system can serve as a promising theragnostic system of early warning and diagnosis for liver fibrosis, offering hope against progression of this serious liver condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
- Department of Chemistry and Biochemistry, Florida International University, Miami, FL, 33199, USA.
- The Public Laboratory Platform, China Pharmaceutical University, Nanjing, 211198, China.
- Institute of Innovative Drug Discovery and Development, China Pharmaceutical University, Nanjing, Jiangsu, 211198, China.
ORCID-Profile: Juanjuan Peng
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Wang, L., Zhou, J., Wang, J., Wang, X., Dong, H., Zhao, L., Wu, J., & Peng, J. (2024). Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202303710
Vancouver
Wang L, Zhou J, Wang J, Wang X, Dong H, Zhao L, et al. Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202303710
BibTeX
@article{Wang2024,
author = {Wang, Lei and Zhou, Jieying and Wang, Jian and Wang, Xiaotang and Dong, Haijuan and Zhao, Lingzhi and Wu, Junchen and Peng, Juanjuan},
title = {Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202303710}
}
EUVIMED